Edition:
United States

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

4.26USD
3:59pm EST
Change (% chg)

$0.09 (+2.16%)
Prev Close
$4.17
Open
$4.20
Day's High
$4.32
Day's Low
$4.17
Volume
2,456
Avg. Vol
13,040
52-wk High
$5.83
52-wk Low
$2.68

Latest Key Developments (Source: Significant Developments)

Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​
Monday, 22 Jan 2018 08:14am EST 

Jan 22 (Reuters) - Flex Pharma Inc ::FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​.  Full Article

Flex Pharma Q3 loss per share $0.54
Monday, 6 Nov 2017 08:00am EST 

Nov 6 (Reuters) - Flex Pharma Inc ::Flex Pharma reports third quarter 2017 financial results.Q3 loss per share $0.54.Q3 revenue $414,000 versus I/B/E/S view $477,000.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - ‍expects to have sufficient capital to fund operations into early 2019​.  Full Article

Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Flex Pharma Inc :Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS.Flex Pharma - ‍data from exploratory phase 2 trial of FLX-787 showed statistically significant reduction in cramp-associated pain intensity & stiffness​.Flex Pharma Inc - ‍FLX-787 was generally well tolerated​.  Full Article

Flex Pharma initiates CMT phase 2 trial with FLX-787 in US
Monday, 16 Oct 2017 08:30am EDT 

Oct 16 (Reuters) - Flex Pharma Inc :Flex Pharma initiates CMT phase 2 trial with FLX-787 in US.Flex Pharma Inc - ‍ALS phase 2 trial currently underway​.Flex Pharma Inc - ‍expects to report topline results from this study in middle of 2018​.  Full Article

Flex Pharma Q2 loss per share $0.51
Wednesday, 2 Aug 2017 07:30am EDT 

Aug 2 (Reuters) - Flex Pharma Inc :Flex Pharma reports second quarter 2017 financial results.Q2 loss per share $0.51.Q2 revenue $336,000.Q2 revenue view $515,000 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - expects to have "sufficient" capital to fund its operations into early 2019.  Full Article

Flex Pharma initiates ALS phase 2 trial with flx-787 in U.S.
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Flex Pharma Inc :Flex Pharma initiates ALS phase 2 trial with flx-787 in us.Says expects to report topline results from this study in middle of 2018.Says also intends to initiate a phase 2 clinical trial in cmt this quarter.  Full Article

Flex Pharma names William Mcvicar president and chief executive officer
Monday, 31 Jul 2017 07:30am EDT 

July 31 (Reuters) - Flex Pharma Inc :Flex pharma names William Mcvicar president and chief executive officer.Flex Pharma Inc says are on track to initiate phase 2 clinical trials of flx-787 in both als and cmt this quarter in U.S..Flex Pharma Inc - appointed william mcvicar, ph.d. as president and chief executive officer of flex pharma.  Full Article

FDA grants fast track designation to Flex Pharma’s FLX-787
Tuesday, 25 Jul 2017 07:30am EDT 

July 25 (Reuters) - Flex Pharma Inc :FDA grants fast track designation to Flex Pharma’s FLX-787 for the treatment of severe muscle cramps associated with ALS.‍Phase 2 trials in ALS and CMT to commence in us this quarter​.‍Phase 2 trials in ALS and CMT to commence in us this quarter​.‍Prioritizing US phase 2 commend trial; exploratory Australian ALS study to end early​.  Full Article

Flex Pharma Inc says Christoph Westphal to step down as CEO
Monday, 5 Jun 2017 04:10pm EDT 

June 5 (Reuters) - Flex Pharma Inc : :Flex Pharma Inc - Christoph Westphal to step down as CEO and will continue as chair of board.Flex Pharma Inc - board appoints flex executive William Mcvicar as interim CEO.Flex Pharma Inc - Mcvicar joined Flex Pharma in April 2017 as president of research & development.  Full Article

Flex Pharma says US Phase 2 trial of FLX-787 in CMT patients to start this summer
Friday, 2 Jun 2017 08:00am EDT 

June 2 (Reuters) - Flex Pharma Inc :Flex Pharma’S Phase 2 trial with FLX-787 in charcot-marie-tooth endorsed by the inherited neuropathies consortium.Flex Pharma Inc says US Phase 2 trial of FLX-787 in CMT patients to start this summer.  Full Article

BRIEF-Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​

* FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​ Source text: (http://bit.ly/2F0i8Tu) Further company coverage: